ClinicalTrials.gg
Not yet recruitingNCT07848945Updated Sep 30, 2026

Phase I Study of JY1001 Injection

A Phase 1 interventional study of JY1001 and Placebo in Pain After Surgery, sponsored by Jemincare. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Jemincare · Phase 1, Interventional, and Treatment

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Pain with a site in China — 65 open to participants now, 71 under way, 2 of them phase 3. Pain · China.

Planned enrollment
168th of 210
48 · median 120
Started
2026
with 22 others
Phase 1
17 of 245
4 open now
Primary completion
2027-05
later than 38 of 70 live
Registered
243rd of 245
by date

Among the 245 studies in Pain with a site in China, this one is the 168th largest by planned enrollment of the 210 interventional ones that give a count, is one of 23 that started in 2026, is one of 17 in phase 1, reaches primary completion later than 38 of the 70 other live ones, and was the 243rd registered.

Pain

10,071 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

65 of the 245 studies in Pain with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Pain with a site in China, or all of them as a file.
02

Study summary

The goal of this dose esclation study is to evaluate the safety, tolerability, and PK characteristicsafter of a single dose of JY1001 injection in healthy participants. A total of 6 cohorts are planned to be evaluated. Each cohort will enroll 8 participants to receive JY1001 or placebo in 3:1 ratio.

Read the detailed description

This is a randomized, double-blind, placebo-controlled Phase I clinical trial to evaluate the safety, tolerability, and PK characteristics of a single dose of JY1001 in healthy participants.

Healthy participants will be randomized to receive JY1001 or placebo (8 participants each cohort, with a ratio of 3:1). The study includes 6 cohorts. JY1001 doses levels in each cohort will be 10 mg, 20 mg, 40 mg, 80 mg, 160 mg, and 320 mg, respectively. Eligible participants will stay at the study center one day before administration (D-1) and receive the drug at D1. They will be discharged on D4 (72 hours after administration).

Decisions on dose escalation to next cohort will be made by Safety Review Committee (SRC) consisting of investigators and sponsor representatives, based on all participants' safety and tolerability data up to 72 hours after administration and any available PK data of the previous cohort.

03

Conditions studied

  • Pain After Surgery

Browse trials for

Keywords

  • dose esclation
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female adult participants
  • Men ≥50kg, women ≥45kg, and (BMI) 19-28 kg/m² (inclusive)

Exclusion criteria

Exclusion Criteria:

  • With any disease that the investigator judges will take risk to participants or affect the evaluation of the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    JY1001

    Drug: JY1001

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugJY1001

    Participants will receive a single dose of JY1001 (10 mg, 20 mg, 40 mg, 80 mg, 160 mg, 320 mg) via IV at Day 1

  • DrugPlacebo

    Participants will receive a single dose of placebo via IV at Day 1

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Incidence of Adverse events (AEs)

    Time frame: Day 1 to Day 4

Secondary outcomes

  1. Maximum concentration (Cmax)

    Cmax was the highest concentration observed directly from data

    Time frame: Day 1 to Day 4

  2. Area under the concentration-time curve

    Reflects the actual body exposure to drug after administration of sinlge and multiple dose

    Time frame: Day 1 to Day 4

  3. Time to Cmax (Tmax)

    Tmax was the time to reach maximum observed plasma concentration

    Time frame: Day 1 to Day 4

  4. Elimination half-life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Day 1 to Day 4

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2027, 6 months later.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's planned 6 months is above that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 30, 2026
StartEst.
Nov 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848945
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Nov 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Mengchang Yang
Contact
ymc681@126.com
028-87394243

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion